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Background: We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifun-
gal prophylaxis (AP) in a ‘real-life’ setting of patients with AML receiving intensive consolidation therapy.
Methods: Cases of IA, observed during consolidation in adult/paediatric patients with AML between 2011 and
2015, were retrospectively collected in a multicentre Italian study.
Results: Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed
in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P"0.01). Number-
needed-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP)
for one additional patient to not have IA. Initial antifungal therapy was ‘pre-emptive’ in 36 (64%) patients and
‘targeted’ in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly
those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P"0.001]. The overall mortality rate and the mor-
tality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age 60 years
(OR"12.46, 95% CI"1.13–136.73; P"0.03) and high-dose cytarabine treatment (OR"10.56, 95% CI"1.95–
116.74; P"0.04) independently affected outcome.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For permissions, please email: journals.permissions@oup.com.
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Conclusions: In our experience, AP appears to prevent IA from occurring during consolidation. However, al-
though the incidence of IA was low, mortality was not negligible among older patients. Further prospective stud-
ies should be carried out particularly in elderly patients treated with high-dose cytarabine to confirm our data
and to identify subsets of individuals who may require AP.
Introduction
Over recent years, considerable progress has been made in under-
standing AML pathogenesis and in the development of diagnostic
assays and novel therapies.1 Despite these advances2 the out-
come of AML remains poor due to features intrinsic to the disease
or due to complications, such as infections, occurring as a side ef-
fect of the intensive regimens that are adopted. Among infections,
invasive aspergillosis (IA) is one of the most frequent conditions in
AML. IA can be life-threatening and very difficult to eradicate, so
that the normal chemotherapeutic course can be substantially
altered, compromising the attempt of a successful cure of underly-
ing AML.
Accordingly, efforts have been made to implement strategies
of antifungal prophylaxis (AP) to prevent IA. Cornely et al.3 demon-
strated that a prophylaxis with posaconazole, given during neutro-
penia following AML induction therapy, was superior to a
prophylaxis with itraconazole or fluconazole in preventing proven/
probable invasive fungal infection and was associated with relative
reduction of mortality. Several retrospective studies confirmed
these results4–6 and current international guidelines recommend
prophylaxis with posaconazole during the induction phase, based
on the high level of evidence.7–10
However, investigators focused on the role of AP given during
the induction chemotherapy of AML, with few studies exploring
whether there was a role for AP also in patients receiving consoli-
dation chemotherapy. The reason for this lack of interest is that
the incidence of IA during consolidation therapy is considered a
rare event,11–16 although such a perception does not rely on robust
evidence. As a matter of fact, the epidemiology of IA in the induc-
tion phase has been extensively investigated, whereas only limited
data are available with regards to the incidence and characteristics
of IA occurring during consolidation. Actually, considering the bone
marrow suppression following consolidation chemotherapy,
patients are at risk of developing IA even in this phase of the thera-
peutic programme. Similarly to induction, a diagnosis of IA during
consolidation does have a potential impact on prognosis, since it
may cause a delay in the subsequent therapeutic programme and
prolong hospitalization, eventually increasing the overall costs of
disease. Furthermore, while, among the different haematological
centres, there is a consensus about the adopted strategies of AP
during induction, the prophylaxis during consolidation varies
consistently.
Based on these observations, we analysed, retrospectively, a
large ‘real-life’ series of patients with AML with the aim to: (i) evalu-
ate the current rate of proven and probable IA in patients with AML
submitted to intensive consolidation therapy; (ii) identify risk fac-
tors that, following consolidation, are associated with IA; and (iii)
assess the role of AP as delivered either in induction or consolida-
tion in preventing IA from occurring after consolidation therapy.
Methods
This retrospective multicentre study was conducted between January 2011
and December 2015, in 38 Italian haematology units affiliated with the
Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) consortium.
The incidence of probable and proven IA was assessed according to the
revised European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)
criteria.17
Cases were documented using a case report form. Variables included
the following data: age, gender, AML onset, genetic/cytogenetic risk fac-
tors,1 duration of neutropenia (,10 versus 10 days), comorbidity condi-
tions (diabetes, COPD, renal/hepatic failure), mucosal damage, diarrhoea,
steroid administration and details of chemotherapeutic regimens. The clin-
ical characteristics of patients with IA were compared with those of a con-
trol group, including 102 individuals matched for age and treatment,
selected in the same period and in the same centres. Additional data col-
lected were: AP, infections, site of infection, diagnostic microbiology, (direct
microscopy, cultures, and galactomannan assay in serum or in bronchoal-
veolar lavage), imaging and histology, date of antifungal therapy initiation
and whether this was ‘pre-emptive’ or ‘targeted’, and date of death. ‘Pre-
emptive’ treatment was initiated in patients with persistent fever and
imaging suspected of having IA. In patients with compatible radiological
signs and microbiological tests allowing identification of the pathogen and
in those with histopathological evidence of an aspergillosis, ‘targeted’ ther-
apy was initiated. The assessment of response to therapy relied on clinical
evaluation, quantitative laboratory tests and to a lesser extent imaging
studies.18,19 Death was defined as early (,30 days) or late (.30 days) after
the diagnosis of IA. Mortality was regarded as attributable to IA if the pa-
tient died within 120 days since consolidation initiation and had microbio-
logical, histological or clinical evidence of IA and when any alternative
cause had been excluded.
Statistical analysis
Continuous variables were compared with Student’s t-test (for normally
distributed variables) or the Mann–Whitney U-test (for non-normally dis-
tributed variables). Categorical variables were evaluated with the v2 or two-
tailed Fisher’s exact test. ORs and 95% CIs were calculated for all associa-
tions that emerged. Results are expressed as mean+ SD or median (range)
(continuous variables) or as percentages of the group from which they
were derived (categorical variables). Two-tailed tests were used to deter-
mine statistical significance; P,0.05 was considered significant.
Multivariate analysis was used to identify independent risk factors for mor-
tality. For this analysis, we used logistic regression, and variables found to
be significant in univariate testing were incorporated with a stepwise ap-
proach. The number needed to treat to achieve one additional patient free
from IA was calculated as the reciprocal of the rate difference between AP
and no prophylaxis.
Ethical considerations
Approval of the local institutional review board and ethics committee was
obtained at all participating sites.
Results
Of 2588 patients in complete remission after induction therapy
and therefore submitted to consolidation, 56 (2.2%) developed
IA. Cases of IA probable predominated over histologically pro-
ven cases [43 (1.7%) versus 13 (0.5%)]. Characteristics of the 56
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patients with IA are summarized in Table 1. As consolidation
therapy, 14 (25%) patients received standard-dose cytarabine
(100 mg/m2, days 1–5, continuous infusion), 21 (37.5%)
patients received intermediate-dose cytarabine (500 mg/m2
every 12 h, days 1–6) and 21 patients received high-dose cytar-
abine (2 g/m2/day, days 1–5 or 1, 3, 5 and 7). Thirty-four
patients were also given anthracycline together with cytara-
bine. The lung was the most frequently involved site (50 of 56;
89%); 8 patients (14%) had a disseminated IA with at least
three sites involved. Four patients also presented a history of IA
during the induction phase. No significant differences were
observed between patients who developed proven IA and those
with probable IA (see Table 1).
Risk factors
To identify potential risk factors associated with the development
of proven/probable IA during/after consolidation therapy, we com-
pared the clinical characteristics of patients diagnosed with IA
with those of the control group. In univariate analysis none of the
variables analysed were significantly associated with the risk of IA
during consolidation (see Table 2).
Prophylaxis during induction and consolidation
Most patients (2199, 85%) received prophylactic posaconazole dur-
ing the previous induction phase while the remaining 389 (15%)
received other antifungal agents. There were no significant differ-
ences in the incidence of IA after consolidation based on the type
of AP delivered in the induction (posaconazole versus other agents).
On the other hand, delivering AP in consolidation was associated
with a significant benefit. In fact, the diagnosis of IA was made in
34 of 1137 (2.9%) patients who did not receive AP and in 22 of
1451 who did receive it (1.5%) (P,0.01). The number needed to
treat to achieve one additional patient who will benefit from the AP
was 71. In other words, on average, 71 patients would have to re-
ceive AP (instead of no AP) for one additional patient to not have IA.
Table 3 summarizes the distribution of patients in the different
consolidation-course AP groups.
Furthermore, AP was able to reduce the failure of the first anti-
fungal therapy. In fact, the success of antifungal therapy was
observed in 16 of 22 (73%) patients who received AP and in 10 of
34 (29%) who did not receive AP (P"0.001).
Treatment and response to antifungal therapy
‘Pre-emptive’ antifungal therapy was started in 36 patients (64%),
mainly with liposomal amphotericin B [22 (61%); P,0.0005],
while the remaining 20 (37%) received a ‘targeted’ approach.
Thirteen patients switched from liposomal amphotericin B to vori-
conazole, so that the most frequently targeted antifungal therapy
was voriconazole (28 of 56, 50%). Combined therapy was given as
first-line targeted therapy in four patients (7%). The most frequent
combination was liposomal amphotericin B plus voriconazole.
Efficacy of treatment was assessed by the rate of success of the
first-line therapy. Of 56 patients, 26 (46%) had a good response.
However, when considering the drugs most frequently used in
first-line therapy, no significant differences emerged in univariate
analysis with regard to outcome (Table 4).
Outcome
The early mortality rate was 9% (5 of 56) while the late mortality
rate was 16% (9 of 56). No significant inter-centre differences
were observed. Death due to IA or occurring in the presence of IA
(mortality attributable to IA) occurred in 7% of patients (4 of 56) by
day 30 and in 9% (5 of 56) by day 120. Other causes of mortality
were bacterial infections and AML progression (the latter particu-
larly for late deaths). Univariate analysis showed that the parame-
ters that influenced outcome were the duration of neutropenia
10 days, treatment with high-dose cytarabine or age 60 years
(see Table 4). Multivariate analysis confirmed that age 60 years
(OR"12.46, 95% CI"1.13–136.73; P"0.03) and high-dose cytara-
bine (OR"10.56, 95% CI"1.95–116.74; P"0.04) were factors that
Table 1. Clinical characteristics of patients who developed a proven/
probable IA after consolidation treatment
Patient characteristic Total
Proven
IA
Probable
IA P
Total number of patients 56 13 43
Gender, n (%) 0.21
male 38 (68) 7 (54) 31 (72)
female 18 (32) 6 (46) 12 (28)
Age (years) 0.95
median 59 60 58
range 5–79 5–71 15–79
50, n (%) 37 (66) 9 (69) 28 (65)
,50, n (%) 19 (34) 4 (31) 15 (35)
Comorbidity, n (%) 0.93
yes 35 (63) 8 (62) 27 (63)
no 21 (37) 5 (38) 16 (37)
Inpatient stay (days) 0.80
median 31 39 31
range 3–114 3–114 8–79
Cytogenetic/genetic risk
group, n (%)
0.72
favourable 22 (40) 5 (38) 17 (39)
intermediate 17 (30) 5 (38) 12 (28)
adverse 12 (21) 2 (16) 10 (23)
unknown 5 (9) 1 (8) 4 (10)
Year of observation, n (%) 0.15
2011 5 (9) 0 5 (12)
2012 5 (9) 3 (23) 2 (5)
2013 13 (23) 3 (31) 10 (23)
2014 17 (30) 4 (23) 13 (30)
2015 16 (29) 3 (23) 13 (30)
Central venous catheter, n (%) 0.35
yes 51 (91) 11 (85) 40 (93)
no 5 (9) 2 (25) 3 (7)
Cytarabine dose, n (%) 0.86
standard 14 (25) 5 (38) 16 (37)
intermediate/high 42 (75) 8 (62) 27 (63)
Mucositis (Grade .2), n (%) 0.28
yes 15 (27) 2 (15) 13 (30)
no 41 (73) 11 (85) 30 (70)
Steroid therapy, n (%) 0.87
yes 16 (28) 4 (31) 12 (28)
no 40 (72) 9 (69) 31 (72)
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independently affected outcome. Taking into account the overall
population receiving the consolidation course, the overall mortality
rate and the mortality rate attributable to IA on day 120 were
0.34% and 0.19%, respectively.
Discussion
This retrospective study focuses on the incidence of proven/prob-
able IA and the role of AP in a multicentre large ‘real-life’ series of
consecutive adult and paediatric patients with AML submitted to
consolidation chemotherapy. Overall, the incidence of IA was
2.2%: our observation is comparable to that reported in the past
decade, in which the frequency of invasive fungal infection ranged
from 2%16,20 to 3%.13 Thus, although significant progress has
been made in the cure of patients with AML, the incidence of IA
after consolidation is stable over time.
Owing to the inhalation of dormant spores from the environ-
ment, the lung is the most frequent site of IA development.13 The
Aspergillus spores break quiescence and grow in the human lung,
exploiting the neutropenia and mucosal damage.18 The pivotal
role of neutrophils in the host defence against Aspergillus
infections is well known,21,22 particularly when mucosal barriers
have been disrupted. As reported in other studies23–25 the use of
high-dose cytarabine-based regimens was not associated with a
higher incidence of IA. However, in our experience, treatment with
high-dose cytarabine had a significant impact on the mortality
rate attributable to IA, due to the profound neutropenia and exten-
sive gastrointestinal mucosal damage associated with the admin-
istration of this high-dose regimen. In addition, the profound
neutropenia occurring after high-dose cytarabine may represent
the reason explaining such a correlation, as previously reported.13
Finally, in multivariate analysis we found that age is an independ-
ent factor affecting the outcome. Indeed, almost all deaths due to
IA were observed in patients aged60 years.
We wanted also to explore the role of AP, given in induction and
consolidation, in preventing IA from occurring after consolidation.
The AP during induction did not show a protective effect on the
onset of IA during the consolidation phase of the chemotherapeu-
tic programme. Such a lack of benefit may depend on the fact that
the patients, immunosuppressed and frail, acquire the infection in
the community, after hospital discharge.26 Otherwise, posacon-
azole may control subclinical fungal infection or colonization at the
time of prophylaxis,27 reducing but not abrogating the risk of an
overt infection at the time of subsequent episodes of
immunosuppression.
The centres involved in this survey had different antifungal poli-
cies during the AML consolidation phase. Indeed, about half of
them did not deliver AP, while the others used mould-active
prophylaxis. Itraconazole was the most frequently dispensed drug,
followed by posaconazole. The choice of some centres to use
posaconazole was dictated by different reasons such as ongoing
construction works nearby the hospital, absence of a laminar air
flow room28 or physicians’ simple opinion that the patients were at
high risk of developing IA. The results from our study show that in a
large real-world setting, mould-active AP with itraconazole or
posaconazole decreases the rate of IA after the consolidation
course. The rate of our proven/probable breakthrough IA in
patients treated with posaconazole was in line with the others’
experience.29
In our experience, AP appears to reduce the risk of IA after the
consolidation course and strengthens the efficacy of antifungal
therapy. Most of the patients who received AP responded well
when the first-line antifungal therapy was instituted, and there-
fore we can assume that a broad-spectrum AP may decrease the
rate of resistant pathogens, enhancing the action of the subse-
quent antifungal therapeutic regimen. The beneficial effect of
prophylaxis was translated into number needed to treat, a metric
of comparative efficacy that can be utilized to inform decision-
making in clinical practice.
Our observation is in line with other studies previously
reported30,31 and does not seem to confirm the increase of resist-
ant Aspergillus species in breakthrough infections, although it
remains difficult to draw any firm conclusion due to the low num-
ber of proven cases. Alternatively, AP may reduce the burden of
fungal infections resulting in the occurrence of less severe forms of
IA, which may better respond to antifungal treatment.
With the limitations of its retrospective nature, our study dem-
onstrates that, in patients with AML, IA remains, even in consolida-
tion, a rare but potentially life-threatening complication mainly
among older patients treated with high-dose cytarabine.
Table 2. Univariate analysis of clinical characteristics of controls and IA
cases
Variable Controls IA cases P
Total number of patients 102 56
Gender, n (%) 0.72
male 66 (65) 38 (68)
female 36 (35) 18 (32)
Age (years) 0.17
median 57 59
range 1–79 5–79
50, n (%) 56 (55) 37 (66)
,50, n (%) 46 (45) 19 (34)
Comorbidity, n (%) 0.16
yes 54 (53) 35 (63)
no 48 (47) 21 (37)
Cytogenetic/genetic risk
group, n (%)
0.88
favourable 42 (41) 22 (40)
intermediate 28 (37) 17 (30)
adverse 32 (22) 12 (21)
unknown 0 5 (9)
Neutropenia .10
days, n (%)
0.13
yes 91 (89) 51 (91)
no 11 (11) 5 (9)
Cytarabine dose, n (%) 0.58
standard 30 (30) 14 (25)
intermediate/high 72 (70) 42 (75)
Mucositis (Grade .2), n (%) 0.72
yes 30 (29) 15 (27)
no 72 (71) 41 (73)
Steroid therapy, n (%) 1
yes 25 (25) 16 (28)
no 77 (75) 40 (72)
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Furthermore, our data support the protective role of mould-
active AP in this category of patients. Balancing the clinical efficacy
versus the cost-effectiveness, in our opinion the use of AP during
consolidation should be limited to older patients receiving high-
dose cytarabine. Prospective randomized studies should be per-
formed to confirm our data and to identify the subset of patients
who require anti-mould prophylaxis even during consolidation
chemotherapy.
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